Vojdani, Aristo
Inc,
United States
2025 Rank: 53077
Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Clinical Medicine
SubField 1:
Immunology
SubField 2:
Toxicology
Rank in SubField 1: 1013 out of 166615 Researchers
Data For The Year: 2025
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 53077 | 52475 |
| Total Cites | 382 | 426 |
| H-index | 9 | 10 |
| Hm-index | 5 | 5 |
| Number of Single Authored Papers | 25 | 25 |
| Total Cites to Single Authored Papers | 36 | 37 |
| Number of Single+First Authored Papers | 107 | 107 |
| Total Cites to Single+First Authored Papers | 274 | 293 |
| Number of Single+First+Last Authored Papers | 135 | 135 |
| Total Cites to Single+First+Last Authored Papers | 308 | 334 |
| Composite Score | 2 | 2 |
| Number of Distinct Citing Papers | 342 | 363 |
| Ratio of Total Citations to Distinct Citing Papers | 1.12 | 1.17 |
| Self-Citation Percentage |
10.33%
|
|
Vojdani, Aristo
Immunosciences Laboratories, Inc.,
United States
2024 Rank: 48065
Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Clinical Medicine
SubField 1:
Immunology
SubField 2:
Toxicology
Rank in SubField 1: 963 out of 157372 Researchers
Data For The Year: 2024
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 48065 | 42173 |
| Total Cites | 452 | 524 |
| H-index | 8 | 9 |
| Hm-index | 4 | 5 |
| Number of Single Authored Papers | 25 | 25 |
| Total Cites to Single Authored Papers | 36 | 38 |
| Number of Single+First Authored Papers | 104 | 104 |
| Total Cites to Single+First Authored Papers | 349 | 386 |
| Number of Single+First+Last Authored Papers | 129 | 129 |
| Total Cites to Single+First+Last Authored Papers | 380 | 417 |
| Composite Score | 2 | 3 |
| Number of Distinct Citing Papers | 389 | 418 |
| Ratio of Total Citations to Distinct Citing Papers | 1.16 | 1.25 |
| Self-Citation Percentage |
13.74%
|
|
Vojdani, Aristo
Immunosciences Laboratories, Inc.,
United States
2023 Rank: 52190
Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Clinical Medicine
SubField 1:
Immunology
SubField 2:
Toxicology
Rank in SubField 1: 1154 out of 147556 Researchers
Data For The Year: 2023
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 52190 | 45967 |
| Total Cites | 429 | 489 |
| H-index | 7 | 8 |
| Hm-index | 4 | 5 |
| Number of Single Authored Papers | 25 | 25 |
| Total Cites to Single Authored Papers | 36 | 39 |
| Number of Single+First Authored Papers | 103 | 103 |
| Total Cites to Single+First Authored Papers | 382 | 408 |
| Number of Single+First+Last Authored Papers | 124 | 124 |
| Total Cites to Single+First+Last Authored Papers | 406 | 436 |
| Composite Score | 2 | 3 |
| Number of Distinct Citing Papers | 397 | 422 |
| Ratio of Total Citations to Distinct Citing Papers | 1.08 | 1.16 |
| Self-Citation Percentage |
12.27%
|
|
Vojdani, Aristo
Immunosciences Laboratories, Inc.,
United States
2022 Rank: 117825
Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Clinical Medicine
SubField 1:
Immunology
SubField 2:
Toxicology
Rank in SubField 1: 2710 out of 138599 Researchers
Data For The Year: 2022
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 117825 | 88797 |
| Total Cites | 245 | 302 |
| H-index | 6 | 7 |
| Hm-index | 3 | 4 |
| Number of Single Authored Papers | 25 | 25 |
| Total Cites to Single Authored Papers | 20 | 26 |
| Number of Single+First Authored Papers | 99 | 99 |
| Total Cites to Single+First Authored Papers | 197 | 226 |
| Number of Single+First+Last Authored Papers | 120 | 120 |
| Total Cites to Single+First+Last Authored Papers | 220 | 253 |
| Composite Score | 2 | 2 |
| Number of Distinct Citing Papers | 217 | 237 |
| Ratio of Total Citations to Distinct Citing Papers | 1.13 | 1.27 |
| Self-Citation Percentage |
18.87%
|
|
Vojdani, Aristo
Immunosciences Laboratories, Inc.,
United States
2021 Rank: 126209
Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Clinical Medicine
SubField 1:
Toxicology
SubField 2:
Immunology
Rank in SubField 1: 522 out of 53247 Researchers
Data For The Year: 2021
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 126209 | 100045 |
| Total Cites | 269 | 339 |
| H-index | 7 | 9 |
| Hm-index | 4 | 5 |
| Number of Single Authored Papers | 24 | 24 |
| Total Cites to Single Authored Papers | 46 | 57 |
| Number of Single+First Authored Papers | 93 | 93 |
| Total Cites to Single+First Authored Papers | 191 | 221 |
| Number of Single+First+Last Authored Papers | 114 | 114 |
| Total Cites to Single+First+Last Authored Papers | 224 | 264 |
| Composite Score | 2 | 2 |
| Number of Distinct Citing Papers | 239 | 270 |
| Ratio of Total Citations to Distinct Citing Papers | 1.13 | 1.26 |
| Self-Citation Percentage |
20.65%
|
|
Vojdani, Aristo
Immunosciences Laboratories, Inc.,
United States
2020 Rank: 153376
Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Clinical Medicine
SubField 1:
Complementary & Alternative Medicine
SubField 2:
Toxicology
Rank in SubField 1: 49 out of 9518 Researchers
Data For The Year: 2020
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 153376 | 108247 |
| Total Cites | 151 | 199 |
| H-index | 7 | 8 |
| Hm-index | 3 | 4 |
| Number of Single Authored Papers | 23 | 23 |
| Total Cites to Single Authored Papers | 35 | 46 |
| Number of Single+First Authored Papers | 88 | 88 |
| Total Cites to Single+First Authored Papers | 106 | 142 |
| Number of Single+First+Last Authored Papers | 108 | 108 |
| Total Cites to Single+First+Last Authored Papers | 126 | 172 |
| Composite Score | 2 | 2 |
| Number of Distinct Citing Papers | 139 | 149 |
| Ratio of Total Citations to Distinct Citing Papers | 1.09 | 1.34 |
| Self-Citation Percentage |
24.12%
|
|
Related Profiles
Featured Profiles
Partner with TOPSCINET
Reach science enthusiasts and researchers across the site. Write to business@topscinet.com and our marketing team will send a proposal built around your banner ad goals.